Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics  was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Company Growth (employees)
Hampton, US
Size (employees)
196 (est)
Celldex Therapeutics is headquartered in Hampton, US

Key People at Celldex Therapeutics

Anthony S. Marucci

Anthony S. Marucci

Founder, President & CEO
Avery W. Catlin

Avery W. Catlin

Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Harry H. Penner

Harry H. Penner

Co - Founder

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
220 53 I 78 Frontage Rd
Needham, US
119 4th Ave
Fall River, US
U Mass Dartmouth Center For Innovation & Entrepreneurship 151 Martine St
Branford, US
1a 688 E Main St

Celldex Therapeutics Data and Metrics

Celldex Therapeutics Financial Metrics

Celldex Therapeutics's revenue was reported to be $5.5 m in FY, 2015 which is a 53% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

5.5 m

Revenue growth (FY, 2014 - FY, 2015), %


Net income (FY, 2015)

(127.2 m)

EBIT (FY, 2015)

(129.5 m)

Market capitalization (24-May-2017)

387.8 m

Closing share price (24-May-2017)


Cash (31-Dec-2016)

42.5 m
Celldex Therapeutics's current market capitalization is $387.8 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015


4.1 m3.6 m5.5 m

Revenue growth, %


Operating expense total

85.6 m126 m


(81.4 m)(122.4 m)(129.5 m)

EBIT margin, %


Interest expense

927 k927 k

Net Income

(81.6 m)(118.1 m)(127.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


169.4 m28 m72.1 m42.5 m

Accounts Receivable


Current Assets

305.2 m205 m294.9 m195.6 m


10 m10.5 m11.5 m13.2 m


9 m9 m9 m91 m

Total Assets

347.1 m248 m337.6 m383.4 m

Accounts Payable

2.2 m2.6 m1.5 m1.7 m

Current Liabilities

20.4 m24.5 m30.2 m35.2 m

Additional Paid-in Capital

662.7 m672.7 m878.7 m982.3 m

Retained Earnings

(345.7 m)(463.8 m)(591 m)(719.5 m)

Total Equity

319.8 m211.7 m290.1 m265.4 m

Financial Leverage

1.1 x1.2 x1.2 x1.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(81.6 m)(118.1 m)(127.2 m)(128.5 m)

Depreciation and Amortization

1.9 m2.4 m3 m3.1 m

Accounts Receivable


Accounts Payable

7.2 m1.5 m4.9 m(5 m)

Cash From Operating Activities

(67.7 m)(101.5 m)(98.9 m)(113 m)

Purchases of PP&E

(4.2 m)(1.9 m)(4.9 m)(2.8 m)

Cash From Investing Activities

(77.4 m)(41 m)(50.2 m)68.9 m

Cash From Financing Activities

289.6 m1.2 m193.2 m14.5 m

Interest Paid

1.2 m1.2 m1.2 m
Y, 2016

Financial Leverage

1.4 x

Celldex Therapeutics Market Value History

Celldex Therapeutics Company Life and Culture

You may also be interested in